title: Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.
abstract: BACKGROUND
  Gastroesophageal reflux disease (GERD) is common in patients with asthma, suggesting an interaction between the two conditions.
  
  
  OBJECTIVE
  To assess the effect of gastric acid suppression with the proton pump inhibitor esomeprazole on asthma outcomes in subjects with persistent moderate to severe asthma treated with antiinflammatory asthma medication.
  
  
  METHODS
  In this double-blind study, subjects were randomized to receive esomeprazole 40 mg or placebo twice daily for 16 wk. According to nocturnal respiratory symptoms (NOC) and GERD, subjects were divided into three strata: GERD-/NOC+, GERD+/NOC-, and GERD+/NOC+.
  
  
  RESULTS
  A total of 770 subjects were randomized. There was no statistically significant improvement in morning peak expiratory flow (PEF) over placebo in the overall study population: 6.3 L/min (p = 0.061). Over the whole treatment period, in GERD+/NOC+ subjects (n = 350), esomeprazole provided an 8.7-L/min improvement (p = 0.03) in morning PEF, and a 10.2-L/min improvement (p = 0.012) in evening PEF over placebo. Among 307 subjects taking long-acting beta2-agonists, improvements over placebo were observed in morning PEF (12.2 L/min, p = 0.017) and in evening PEF (11.1 L/min, p = 0.024); these improvements were more pronounced in GERD+/NOC+ subjects. Esomeprazole 40 mg twice daily was well tolerated and no safety concerns were noted.
  
  
  CONCLUSIONS
  Esomeprazole improved PEF in subjects with asthma who presented with both GERD and NOC. In subjects without both GERD and NOC, no improvement could be detected.
authors.affiliation: Department of Pulmonary Diseases, Tampere University Hospital, FIN-33521, Tampere, Finland. toni.kiljander@fimnet.fi
authors.forename: Toni O
authors.initials: TO
authors.lastname: Kiljander
authors.forename: Susan M
authors.initials: SM
authors.lastname: Harding
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Field
authors.forename: Mark R
authors.initials: MR
authors.lastname: Stein
authors.forename: Harold S
authors.initials: HS
authors.lastname: Nelson
authors.forename: Jan
authors.initials: J
authors.lastname: Ekelund
authors.forename: Marta
authors.initials: M
authors.lastname: Illueca
authors.forename: Ola
authors.initials: O
authors.lastname: Beckman
authors.forename: Mark B
authors.initials: MB
authors.lastname: Sostek
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D064098:Esomeprazole / Q000008:administration & dosage*; D005260:Female; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D011336:Probability; D011379:Prognosis; D012016:Reference Values; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D064098:Esomeprazole